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Abstract
Bacground/Aim. Visceral fat is highly active metabolic and
endocrine tissue which secretes many adipokines that act
both on local and systemic level. It is believed that adipokines
and "low-grade inflammatory state" represent a potential link
between obesity, metabolic syndrome, insulin resistance and
cardiovascular disease. Leptin and adiponectin are considered
to be the most important adipokines with the potential meta-
bolic and cardiovascular effects. Body weight loss improves
insulin sensitivity and decreases risk for most complications
associated with obesity. The aim of this study was to deter-
mine the effects of moderate loss of body weight on the level
of leptin and adiponectin, insulin sensitivity and abnormalities
of glycoregulation in obese women, to determine whether
and to what extent the secretory products of adipose tissue,
leptin and adiponectin contribute to insulin sensitivity, as well
as to assess their relationship and influence on glycemia and
insulinemia during the period of losing body weight using a
calorie restricted diet. Methods. The study involved 90 obese
female subjects (BMI  30 kg/m2) of different age with
weight loss no less than 5% during a six-month period by ap-
plication of restricted dietary regime. The calorie range was
between 1,100–1,350 kcal. Serum levels of leptin and adipo-
nectin, fasting glucose, fasting insulinemia, and Homeostasis
Model Assessment of Insulin Resistance (HOMA-R) index
were determined in all the subjects initially and after weight
reduction. The presence of glycemic disorders was assessed
on the basis of oral glucose tolerance test  – OGTT. Results.
Applying a 6-month restrictive dietary regime the subjects
achieved an average weight loss of 8.73 ± 1.98 kg and 8.64 ±
1.96%, which led to the reduction of fasting glycemia, fasting
insulinemia and HOMA-R index at the maximum level of
statistical significance (p  < 0.001). The achieved reduction led
to a statistically significant decrease of leptin level and in-
crease of adiponectin level (p < 0.001). The correction of the
established pre-diabetic disorders of glycoregulation was not
statistically significant. There was a statistically significant cor-
relation between the anthropometric parameters, leptin, adi-
ponectin, fasting glycemia, fasting insulinemia and HOMA-R
index. There was a positive correlation between leptin, fasting
insulinemia and HOMA-R, as well as a statistically significant
negative correlation between adiponectin, fasting insulinemia
and HOMA-R index (p < 0.01). Conclusion. Body weight
increase and central fat accumulation lead to changes in se-
rum levels of leptin and adiponectin, reduction of insulin sen-
sitivity and development of glycemic dysregulation. Secretory
products of adipose tissue, leptin and adiponectin contribute
to the genesis of these disorders. The obtained results show
that the effect of adiponectin on insulin sensitivity is more
significant. The analysis of the effects of weight loss on the
investigated parameters shows that moderate weight reduc-
tion by restrictive dietary regime lead to changes of investi-
gated parameters at the maximum level of statistical signifi-
cance. Such results emphasize the importance of weight re-
duction in obese persons, as well as the need for consistent
implementation of restricted dietary regime in the process of
treatment of obesity.
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Apstrakt
Uvod/Cilj. Visceralna mast, visokoaktivno metaboliÿko i
endokrino tkivo, sekretuje mnoge adipokine koji deluju na
lokalnom i sistemskom nivou. Smatra se da su adipokini i
„stanje niskog stepena inflamacije" potencijalna veza izmeĀu
gojaznosti, metaboliÿkog sindroma, insulinske rezistencije i
kardiovaskularnih oboljenja. Kao najvažniji adipokini navode
se leptin i adiponektin. Gubitak telesne mase poboljšava in-
sulinsku senzitivnost i smanjuje rizik od veýine komplikacija
povezanih sa gojaznošýu. Cilj ove studije bio je da se utvrde
efekti umerenog sniženja telesne mase na nivo leptina i adi-
ponektina, insulinsku senzitivnost i poremeýaje glikoregula-
cije kod gojaznih žena, da se utvrdi da li i u kojoj meri se-Volumen 70, Broj 3 VOJNOSANITETSKI PREGLED Strana 285
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kretorni produkti masnog tkiva, leptin i adiponektin, dopri-
nose insulinskoj senzitivnosti, kao i da se proceni njihov me-
Āusobni odnos i uticaj na glikemiju i insulinemiju u toku sni-
žavanja telesne mase primenom kalorijski ograniÿavajuýeg
naÿina ishrane. Metode. Ispitivanjem je obuhvaýeno 90 go-
jaznih žena (BMI  30 kg/m2), kod kojih je u periodu od
šest meseci primene ograniÿavajuýeg dijetetskog režima do-
šlo do gubitka telesne mase ne manjeg od 5%.  Kalorijski ra-
spon kretao se od 1 100–1 350 kcal. Kod svih ispitanica pre i
posle sniženja telesne mase odreĀivan je serumski nivo lepti-
na i adiponektina, glikemija našte, insulinemija našte i Homeo-
stasis Model Assessment of Insulin Resistance (HOMA-R) indeks.
Na osnovu testa oralne tolerancije glikoze (OGTT) vršena je
procena postojanja glikemijskih poremeýaja. Rezultati. Pri-
menom šestomeseÿnog restriktivnog režima ishrane kod is-
pitanica postignut je proseÿni gubitak težine od 8,73 ± 1,98
kg ili 8,64 ± 1,96% što je uslovilo snižavanja nivoa glikemije
našte, insulinemije našte i HOMA-R indeksa na maksimalni
nivo statistiÿke znaÿajnosti, (p < 0,001). Postignuta redukcija
dovela je i do statistiÿki znaÿajnog sniženja nivoa leptina i
porasta nivoa adiponektina (p < 0,001). Korekcija ustanov-
ljenih predijabetesnih poremeýaja glikoregulacije nije bila
statistiÿki znaÿajna. Ustanovljena je statistiÿki znaÿajna kore-
lacija izmeĀu antropometrijskih parametara, leptina, adipo-
nektina, glikemije našte, insulinemije našte i HOMA-R  inde-
ksa. Ustanovljena je pozitivna korelacija izmeĀu leptina, in-
sulinemije našte i HOMA-R indeksa, kao i statistiÿki znaÿaj-
na negativna korelacija izmeĀu adiponektina, insulinemije
našte i HOMA-R indeksa (p < 0,01). Zakljuÿak. Gojaznost i
centralna akumulacija masti dovode do izmene u serumskim
nivoima leptina i adiponektina, sniženja insulinske senzitiv-
nosti i nastanka glikemijske disregulacije. Sekretorni produkti
masnog tkiva, leptin i adiponektin, doprinose nastanku ovih
poremeýaja, pri ÿemu je uticaj adiponektina na insulinsku
senzitivnost, na osnovu dobijenih rezultata, znaÿajniji. Anali-
zom efekata gubitka telesne mase na ispitivane parametre,
pokazano je da je umereno sniženje težine kod veýine ispita-
nica uslovilo znaÿajne promene praýenih parametara. Ovako
postignuti rezultati snažno naglašavaju znaÿaj sniženje teles-
ne mase kod gojaznih osoba, kao i neophodnost doslednog
sprovoĀenja ograniÿavajuýeg naÿina ishrane u procesu leÿe-
nja gojaznosti.
Kljuÿne reÿi:
gojaznost; leptin; adiponektin; telesna masa, indeks;
žene; dijeta, redukciona; insulin, rezistencija.
Introduction
Obesity belongs to a group of most common metabolic
diseases getting epidemic proportions despite public health
education and initiatives to reduce it. It is one of leading
causes of morbidity and mortality in contemporary society.
Numerous studies, including the Framingham one as the
first, clearly identify obesity as an independent cardiovascu-
lar risk factor, pointing out that its association with other
known risk factors, primarily glucose dysregulation and hy-
pertension, leads to enormous increase in the incidence of
cardiovascular diseases 
1.
Obesity induces insulin resistance, or "the state of re-
duced insulin action" in insulin-sensitive tissues with the
consequent hyperinsulinemia, which is the underlying
mechanism in the development of metabolic syndrome and
diabetes mellitus. The prevalence of diabetes type 2 is 5 fold
higher in obese men and 8.3 fold higher in obese women.
The link between insulin resistance and obesity is complex,
and numerous evidence suggests that adipose tissue, as hor-
mone-active system, has effect on insulin action and glucose
and lipid metabolism 
2–4.
Adipose tissue produces a large number of bioactive
molecules, known as "adipokines" (adipocytokine) including
leptin, adiponectin, resistin, visfatin, apelin, TNF-Į, IL-6, etc,
that contribute significantly to the development of metabolic
abnormalities associated with obesity. They participate in the
regulation of appetite and energy balance, immunity, insulin
sensitivity, angiogenesis, blood pressure, lipid metabolism and
hemostasis. The effects of adipokines on vascular function,
immune regulation and fat metabolism, make them key play-
ers in the pathogenesis of the metabolic syndrome, and thus
responsible for development of diabetes and atherovascular
disorders. This refers primarily to leptin and adiponectin 
5–7.
Leptin is one of the first identified adipokines with nu-
merous effects, including effects on energy homeostasis,
neuroendocrine and immune function. Leptin suppresses
food intake, increases energy consumption and regulates
body weight. In humans, leptin levels correlate positively
with body mass index and fat distribution 
8. Clinical condi-
tions with reduced fat mass (lipodystrophy) are characterized
by reduced concentrations of leptin, significant ectopic tri-
glyceride deposition in muscle, liver and ȕ cells and insulin
resistance, whereby administration of leptin significantly im-
proves glycemic control, reduces level of triglycerides and
improves insulin sensitivity. Consequently, inadequate action
of leptin due to leptin resistence, which characterizes obesity,
may contribute to the development of insulin resistance and
glycemic dysregulation 
9, 10.
Along with the increase of fat mass there occurs an in-
crease in the production and secretion of numerous proin-
flammatory/prothrombic adipokines, including TNF-Į, IL-6,
CRP, PAI-1, angiotensinogen. It is recognized that obesity is
a condition characterized by chronic, systemic low-grade in-
flammation, which is significantly supported by decline of
adiponectin 
11–14. The physiological role of adiponectin has
been unclear yet, although it seems that it has significant
anti-inflammatory, vasculoprotective and antidiabetic prop-
erties 
15. Application of recombinant adiponectin in pharma-
cological studies reduces serum glucose in healthy and dia-
betic rodents without stimulation of  insulin secretion, sug-
gesting that it functions primarily as an insulin sensitizer and
then as a regulator of glucose homeostasis. Moreover, pro-
spective studies have shown that low level of adiponectin is
associated with the increased risk of onset of diabetes which
implies its potential role in the pathogenesis of insulin resis-
tance and diabetes
 16. However, some further studies are re-
quired to support this finding 
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proves insulin sensitivity and decreases large number of
complications associated with obesity. However, the
physiological factors that play a role in improving insulin
sensitivity induced by body weight loss have not been fully
identified yet.
The aim of this study was to: determine the effects of
moderate loss of body weight on leptin and adiponectin lev-
els, insulin sensitivity and glycoregulation in obese women
tɨ determine relationships and influence of leptin and adipo-
nectin on glycemia, insulinemia and insulin sensitivity.
Ɇɟthods
The study included 90 obese female subjects (BMI  30
kg/m
2) of different age, who had undergone restrictive hygi-
enic-diet regime for six months and lost no less than 5% of
their body weight. The body weight of the subjects had been
stable for at least three months before they were included in
the study.
The weight-reduction diets were prescribed by a medi-
cal specialist and a dietitian (at the Department of Dietetic
Counseling, the  Institute of Public Health in Niš). The diet
was administered individually based on health condition, en-
ergy needs, anamnestic data on nutrition (nutritional surveys)
and established nutritional status. The calorie range was be-
tween 1,100–1,350 kcal. The study did not include individu-
als with established endocrine cause of obesity, diagnosed
diabetes, clinically significant active cardiovascular disease,
including myocardial infarction within the past six months
and/or heart failure, individuals with chronic renal failure,
liver failure, malignant disease or those with acute or chronic
disease where therapeutic regimen might have affected re-
search results.
For each subject anthropometric measurements and
biochemical analyses were done at the beginning of the stady
and after six months.
Anthropometric measurements – height, weight, waist
(WC) and hip (HC) circumference were measured with the
subject standing. Weight was measured while they were
minimally clothed without shoes, using digital scales and re-
corded to the nearest 100 g. Height was measured in a
standing position without shoes, using a standard anthro-
pometer to the nearest 0.1 cm. The body mass index (BMI)
was calculated as weight in kilograms divided by height in
metres squared (kg/m
2). With the participant standing and
breathing normally, waist circumference was measured
midway between the superior iliac crest and the costal mar-
gin (at the level of the umbilicus), using a tape measure. Hip
circumference was measured at the point of maximum cir-
cumference over the buttocks. Waist to hip ratio (WHR) was
calculated.
Biochemical analyses – blood samples after overnight
fasting were collected for determination of fasting plasma
leptin, adiponectin, glucose (FPG) and insulin.  Fasting
plasma leptin was measured using the ELISA method (DRG
leptin enzyme immunoassay kit), expressed in ng/ml. Fasting
plasma adiponectin was measured using the ELISA method
(DRG human adiponectin enzyme immunoassay kit), ex-
pressed in mg/mL. Fasting plasma glucose was measured
using enzymatic UV test with hexokinase, expressed in
mmol/L (reference range 4.1 to 6.1 mmol/L). Plasma insuli-
nemia was measured by ELISA method (Biosource), using a
test for the quantitative measurement, expressed in mU/L
(reference value to 25.0 mU/L). Insulin resistance was esti-
mated according to homeostasis model assessment (HOMA-
IR) formula [fasting glucose (mmol/L) x fasting insulinemia
(mU/L) / 22.5], where it is assumed that normal weight,
healthy individuals under 35 years of age have an insulin re-
sistance of 1, which correlates well with the values obtained
by means of euglycemic clamp technique 
18).
The oral glucose tolerance test (OGTT) with 75 g glu-
cose dissolved in 300 mL of water was done in all subjects in
order to screen existing disorders of glycemic control ac-
cording to the current World Health Organization (WHO)
classification:
- Normal glucose regulation (NGR) – fasting glyce-
mia  < 6.1 mmol/L and in the second hour OGTT < 7.8
mmol/L;
- Impaired fasting glucose (IFG) – fasting glycemia 
6.1 < 7.0 mmol/L and in the second hour  OGTT < 7.8
mmol/L;
- Impaired glucose tolerance (IGT) – fasting glycemia
< 7.0 mmol/L and in the second hour OGTT  7.8 < 11.1
mmol /L.
Diabetes mellitus (DM) - fasting glycemia  7,0 or in
the second hour OGTT  11,1 mmol/L.
Examination was conducted in the Clinic for Endocri-
nology, Diabetes and Metabolic Diseases, Institute of Nu-
clear Medicine, Clinical Center Niš, Institute of Public
Health in Niš and Biochemical Laboratory “NeoLab” in Niš.
Statistical analysis was performed using SPSS (version
15.0) software. The results  were presented in tables. Data
are presented as frequencies, mean (ʉ), standard deviations
(SD) and 95% confidence interval (95% CI). The Student's t-
test for dependent (paired) samples (with normal distribu-
tions) and Wilcoxon Signed Ranks Test (with distributions
deviating from normal) were done to test the statistical sig-
nificance of differences between the parameters at the begin-
ning and the end of the study. The Ȥ
2-test or Fisher's exact
probability test were used as non-parametric tests to compare
the frequency of some attributive numerical parameters. Us-
ing Spearman’s correlation coefficient – ȡ or the Pearson's
correlation coefficient, – r, respectively, the correlation and
the extent of its significance between the studied parameters
were determined. The strength of correlation defined by
Cohen was asumed as low level – 0.10 to 0.29, mid-level –
0.30 to 0.49 and high level – 0.50 to 1.00 
19.
Results
The examined group consisted of 90 female subjects, of
the average age of 41.77 ± 10.51 years (the youngest being
19, and the oldest 63 years). The coefficient of age variation
was 25.16, indicating group homogeneity.
Obeying a sixth-month restrictive dietary regime the
subjects lost 8.3 ± 1.98 kg or 8.64 ± 1.96% of weight on av-Volumen 70, Broj 3 VOJNOSANITETSKI PREGLED Strana 287
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erage. Of the total number of subjects, 21 (23.33%) achieved
body weight loss  10%.
The basic anthropometric data, values of FPG, insulin,
HOMA-R indeks, leptin and adiponectin are presented in
Table 1. After 6 months of restrictive diatary regime we find
a statisticaly significant reduction of BMI, waist circumfer-
ence, waist/hip ratio, fasting glucose and insulinemia, as well
as HOMA-R index, to the maximal level of statistical sig-
nificance (p < 0.001). The achieved average fasting glycemia
decrease was 0.47 mmol/L. Achieved body weight reduction
caused a change in levels of adipokines, so that after a 6-
month period there was a statistically significant decrease in
leptin levels and a statistically significant increase in adipo-
nectin levels (p < 0.01) (Table 1).
The results of OGTT show that the reduction in body
weight increases the number of normoglycemic subjects
from 62.22% to 71.11% and reduces the number of subjects
with increased fasting glycemia and impaired glucose toler-
ance (Table 2). These changes are not statistically signifi-
cant.
Before and after the body weight reduction we deter-
mined positive statistically significant correlations between
anthropometric parameters (BW and BMI, WC and WHR)
with the level of fasting insulinemia and HOMA-R index.
All these correlations were at medium level (U = 0.30–0.49),
except for a high correlation between the BMI and the
HOMA-R index. Before body weight reduction a significant
positive correlation was determined only between FPG and
WC (p < 0.05). After body weight reduction this correlation
persisted (p < 0.05) and it also became significant between
FPG and BMI (p < 0.01) (Table 3).
A statistically significant positive correlation between
leptin and all anthropometric parameters (p < 0.001)  was
determined before BW reduction. A correlation with body
weight and WHR was at medium level, and with WC and
BMI at high level. There were no significant correlations
after body weight reduction. Correlations of adiponectin with
the tested parameters were negative and low, both before and
after body weight reduction but one should notice a that sta-
tistically significant correlation exists only between adipo-
nectin and BMI as well as adiponectin and WC (p < 0.05)
before weight reduction (Table 4).
Positive low correlations of leptin and a negative correla-
tion of adiponectin with FPG, fasting insulinemia and HOMA-R
index had been established. There was a statistically significant
Table 1
Anthropometric data, FPG, insulin, HOMA-R index, leptin and adiponectin before and after body weight reduction
Parameters Before body weight reduction After body weight reduction
Body weight (kg) 102.37 ± 17.1
*** (97.7–105.96) 93.63 ± 16.58 (90.16–97.11)
BMI (kg/m
2) 36.43 ± 5.42
*** (35.3–35.57) 33.34 ± 5.26 (32.24–34.44)
Waist circumference (cm) 103.12 ± 14.3
*** (100.1–106.1) 93.79 ± 12.71 (91.13–96.45)
Waist/hip ratio 0.89 ± 0.08
*** (0.88–0.83) 0.82 ± 0.06 (0.81–0.83)
FPG (mmol/L) 5.72 ± 0.66
*** (5.58–5.85) 5.25 ± 0.69 (5.11–5.40)
Insulin (mU/L) 27.28 ± 7.36
*** (25.74–28.82) 21.36 ± 5.80 (20.14–22.57)
HOMA-R 6.96 ± 2.10
*** (6.52–7.40) 5.05 ± 1.74 (4.96–5.42)
Leptin (ng/mL) 54.22 ± 25.61
*** (48.85–59.58) 27.09 ± 13.56 (24.25–29.93)
Adiponektin (μg/mL) 7.11 ± 3.30 (6.42–7.80) 10.79 ± 4.60
*** (9.83–11.76)
Data are presented as mean ± SD (95% confidence intervals); FPG – fasting plasma glucose; BMI – body mass index;
HOMA-R – homeostasis model assessment of insulin resistence; *** p < 0.001
Table 2
The oral glucose tolerancie test (OGTT) results before and after body weight reduction
OGTT Before body weight reduction After body weight reduction
NGR 56 (62.22) 64 (71.11)
IFG 9 (10.00) 7 (7.78)
IGT 25 (27.78) 19 (21.11)
Total 90 (100.00) 90 (100.00)
Data are presented as n (%)
NGR – normal glucose regulation; IFG – impaired fasting glucose; IGT – impaired glucose tolerance
Table 3
Correlation between anthropometric parameters and fasting plasma glucose (FPG),
insulin and homeostasis model assessment of insulin resistance – HOMA-R index
Before body weight reduction After body weight reduction
Parameters FPG
(mmol/L) Insulin (mU/L) HOMA-R
index
FPG
(mmol/L)
Insulin
(mU/L)
HOMA-R
index
Body weight (kg) 0.03 0.29** 0.27** 0.15 0.39*** 0.35***
BMI (kg/m
2) 0.20 0.49*** 0.51*** 0.34** 0.60*** 0.58***
Waist (cm) 0.22* 0.38*** 0.42*** 0.23* 0.45*** 0.40***
Waist/hip 0.04 0.37*** 0.33** 0.19 0.38*** 0.34***
The results are expressed as the Spearman’s correlation coefficient – ȡ; *p < 0.05, 
**p < 0.01, 
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negative correlation of adiponectin with fasting insulinemia and
HOMA-R index before body weight reduction (p < 0.01). After
completion of the hygienic-dietetic regimen there was no sig-
nificant correlation (Table 5).
Discussion
Obesity induces increase in insulin levels and insulin
resistance which further aggravates by the increase in BMI
and especially with the increase in visceral fat mass. The
mechanisms that influence this relationship have not yet been
fully explained. There are some possible mediators like high
free fatty acid levels generated by overactive lipolysis in fat,
and changes in adipokines levels produces by adipose tissue,
such as adiponectin and leptin 
20–22.
High levels of free fatty acids interfere with glucose
utilization in muscles and liver and cause various functional
abnormalities (lipotoxicity), including steatohepatitis, reduc-
tion in insulin secretion, and perhaps heart failure 
23–25.
Obesity predisposes to type 2 diabetes primarily by
causing insulin resistance, although some other associated
metabolic abnormalities may contribute to ȕ-cell dysfunc-
tion and increased glycemic values 
26. Nowadays it is con-
sidered that the ȕ-cell function decreases significantly in
the phase of normoglycemia, that is, significantly before
the development of  IGT and severe degree of insulin re-
sistance. Impaired first phase of insulin release and reduced
insulin sensitivity both predict the development of type 2
diabetes. In fact, insulin resistance and ȕ-cell dysfunction
are considered to be essential defects in type 2 diabetes, but
undoubtedly operate to different degrees among individu-
als, whereby obesity contributes to the development of both
disorders 
27.
Since weight gain and central obesity significantly in-
crease the risk of developing disorders of glucose metabo-
lism, OGTT was performed in all subjects in addition to
fasting glycemia. OGTT results show that a total of 37.8%
subjects had prediabetes (10% IFG and 27.78% IGT) and the
largest number of obese people examined had normal glu-
cose regulation. The average value of FPG can be catego-
rized as “high normal fasting glucose”.
Since there is a close link between fasting glycemia and
beta cell function, it is considered that the increase of FPG
within the normal range has already been associated with a
decrease of beta cell function in adults. The state of in-
creased FPG threefold increases the risk of developing type 2
diabetes and may be considered a good marker of acute in-
sulin response 
28, 29. Several previous studies identified high
normal FPG as an independent risk factor for the reduction
of insulin secretion and type 2 diabetes 
30. Reports from the
Bogalusa Heart study showed that adults who developed IGT
or type 2 diabetes had higher values of FPG in childhood and
adolescence, compared with normoglycemic persons 
31.
Nichols et al. 
32 observed a 6% increased risk of developing
type 2 diabetes with each 0.06 mmol/L increase in FPG.
People with FPG levels between 5 to 5.56 mmol /L, were at a
significantly higher risk of developing beta cells disfunction
and diabetes, compared to those whose values were below
4.72 mmol/L 
33.
The achieved body weight reduction caused statistically
insignificant correlation in the frequency of prediabetic dis-
orders, and a statistically significant reduction in fasting gly-
cemia of 0.47 mmol/L in our patients (Table 1).
Other authors also found positive effect of body weight
reduction on glucose control and prevention of diabetes. In
people with prediabetes, who changed their lifestyle and lost
their weight moderately (~ 5%) a reduction in the risk of de-
veloping type 2 diabetes was registered by The Da Qing dia-
betes study over 60%. For example, a great followed 600
people with prediabetes. After six years of follow-up, the in-
cidence of diabetes was 68% in the group of people who re-
ceived no therapy, while the risk of developing diabetes was
reduced to 32%–40% in the intervention group 
34. Finnish
diabetes prevention programme also showed a statistically
significant risk reduction of developing diabetes (by about
60%) in a group of people with prediabetes who had ade-
quate diet and physical activity compared to non-intervention
group. This study also showed the greatest impact of body
weight reduction (4.2 kg), in the very first year of follow-up
35. Similar results were obtained by U.S. diabetes prevention
program, which showed advantage of body weight loss over
Table 4
Correlations between anthropometric parameters and leptin and adiponectin
Before body weight reduction After body weight reduction
Parameters BW (kg) BMI
(kg/m
2) Waist (cm) Waist / Hip BW (kg) BMI
(kg/m
2) Waist (cm) Waist / Hip
Leptin (ng/mL) 0.38*** 0.61*** 0.59*** 0.41*** 0.03 0.03 0.06 0.10
Adiponectin (Pg/mL) -0.13 -0.23* -0.27** -0.01 -0.06 -0.06 -0.15 -0.05
The results are expressed as the Spearman’s correlation coefficient – ȡ; BW – body weight; BMI – body mass index; *p < 0.05, 
**p < 0.01, 
***p < 0.001
Table 5
Correlation of leptin and adiponectin with fasting plasma glucose (FPG), insulin and homeostasis model
assessment of insulin resistance (HOMA-R) index
Before After
Parameters FPG
(mmol/L)
Insulin.
(mU/L) HOMA-R index FPG
(mmol/L)
Insulin.
(mU/L)
HOMA-R
indeks
Leptin (ng/mL) 0.07 0.16 0.20 0.05 0.01 0.04
Adiponectin (Pg/mL) -0.06 -0.30** -0.29** -0.02 -0.08 -0.05
The results are expressed as the Spearman’s correlation coefficient – ȡ; *p < 0.05, 
**p < 0.01, 
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the use of metformin in reducing the incidence of diabetes in
people with prediabetes 
36. Data obtained in Framingham
study suggested that weight loss of more than 6.8 kg reduced
the risk of developing type 2 diabetes by 50% 
37.
Analysing the obtained results it may be observed that
the value of FPG has the strongest correlation with waist cir-
cumference, thus emphasizing the importance of  abdominal
obesity in development of glucose control disorders. After
weight reduction, there was a statistically significant medium
correlation between BMI and FPG (p < 0.01) and WC and
FPG (p < 0.05), which also confirms the importance of re-
duction of both total and visceral fat in improving of glucose
control. The correlation of the average values of BMI, waist
circumference and waist/hip ratio with insulinemia and
HOMA-R index before and after body weight reduction was
positive and statistically significant (Table 3).
The obtained results clearly indicate that body weight
gain and obesity contribute to fasting glycemia increase and
insulin resistance and that weight reduction significantly leads
to their reduction and improvement of cardiometabolic profile.
Although the available literature data highlight stronger effects
of greater weight loss on insulin sensitivity and glucose con-
trol, it is clear that even a slight weight correction (5%–10%)
may lead to a statistically significant improvement in insulin
sensitivity and risk reduction of developing diabetes, which
was actually shown by the results of our study.
It is considered that  adipokines and "low-grade in-
flammatory state" represent a potential link between meta-
bolic syndrome, insulin resistance and cardiovascular dis-
ease. Leptin and adiponectin as hormones with potent meta-
bolic and cardiovascular effects are considered to be the
most important adipokines. Both hormones achieve their ef-
fect by stimulation of AMP-activated protein kinase, a key
enzyme in maintaining cellular energy homeostasis. After its
activation, leptin and adiponectin lead to an increase of fatty-
acid oxidation, thus preventing accumulation of triglycerides
and lipotoxicity, as well as to an increase of glucose trans-
port with a reduction of triglyceride synthesis, lipolysis and
glyconeogenesis, thereby synergistically causing reduction in
the levels of free fatty acids and improved insulin sensitivity.
These hormones also reduce the secretion of important cyto-
kines such as TNF-Į and IL-6, which contribute significantly
to the development of insulin resistance 
38, 39.
Obesity and the increase of  fat mass cause alterations
of adiponectin and leptin levels, thus provoking pathogenic
mechanisms that lead to the development of comorbidity and
higher mortality of these people. Although leptin level rises
parallel with BMI and the increase of body fat mass its effect
is attenuated due to the increase of tissue insensitivity to it,
the phenomenon known as "leptin resistance". On the other
hand, the circulatory levels of adiponectin inversely corre-
lates with BMI and total fat mass, which consequently leads
to its significant reduction in obese persons 
40, 41.
The correlation of adiponectin with anthropometric pa-
rameters before body weight reduction is negative and statisti-
cally significant in relation to BMI and WC (p < 0.001). On the
other hand, the correlation between leptin and these parameters
is statistically significant and positive (Table 4). Fat mass and
its central distribution are important for leptin and adiponectin
levels. Reduction of body weight resulted in a statistically sig-
nificant changes in the level of leptin and adiponectin. The val-
ues of leptin was significantly reduced, while the values of adi-
ponectin in this period was significantly increased (Table 1).
Similar results were confirmed by studies of other authors 
42–45.
Previous studies also indicate that changes in the rela-
tionship between leptin and adiponectin in obese subjects re-
sult in modification of insulin sensitivity and contribute to
the development of insulin resistance 
46–49. For example,
Matsubara et al. 
50 in a study including 486 non-diabetic fe-
males find that adiponectin and leptin are significant predic-
tors of HOMA-R and insulin levels, regardless systolic pres-
sure, BMI and triglycerides.  Zoico et al. 
51 also find that
leptin and adiponectin are strongly related to total fat mass
and insulin resistance in both sexes with values of these
hormones significantly higher in women than in men. Ebinç,
et al. 
22 find that the level of serum adiponectin may repre-
sent a useful marker for identifying individuals at risk of de-
veloping obesity-related diseases, primarily cardiovascular
atherosclerotic disease, regarding the determined difference
of its level and the degree of insulin resistance between me-
tabolically normal obese persons/overweight persons and
obese/overweight persons with associated complications.
These authors suggest that the decline of serum adiponectin
is followed by an increase of HOMA-R index in all groups
of subjects, whereby the largest decrease in adiponectin and
insulin sensitivity was established in the group of obese pa-
tients with dyslipidemia and/or type 2 diabetes. Yamauchi et
al. 
52 suggest that normalization of adiponectin and leptin
levels in obese and diabetic lipoatrophic mice completely
eliminates insulin resistance and improves insulin sensitivity.
The analysis of our results prior to weight loss shows a
positive correlation of leptin and negative correlation of adi-
ponectin with fasting glucose, fasting insulinemia and
HOMA-R index. A statistically significant correlation was
found only between adiponectin with fasting insulinemia and
HOMA-R index (p  <  0.01). This indicates that decreased
level of adiponectin and increased level of leptin in obese
persons have effect on insulin sensitivity, but the effect of
adiponectin was more significant. These results lead to a
conclusion that some other pathogenetic mechanisms, apart
from leptin and adiponectin,  may also play a role in im-
proving metabolic disorders induced by body weight loss.
This issue, however, requires some further investigations.
Conclusion
The analysis of the effects of weight loss on the in-
vestigated parameters shows that moderate weight reduc-
tion, by the restricted diet only, caused changes of these pa-
rameters at the maximum level of significance. Leptin and
adiponectin levels in obese persons have effect on insulin
sensitivity and effect of adiponectin is more significant.
Such results emphasize the importance of weight reduction
in obese persons, as well as the need for consistent imple-
mentation of restricted dietary regime  in the process of
treatment of obesity.Strana 290 VOJNOSANITETSKI PREGLED Volumen 70, Broj 3
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